CSIMarket
 


Regenerx Biopharmaceuticals inc   (RGRX)
Other Ticker:  
 
 

RGRX's Capital Expenditures Growth by Quarter and Year

Regenerx Biopharmaceuticals Inc 's Capital Expenditures results by quarter and year




RGRX Capital Expenditures (in millions $) FY 2023 FY 2022 FY 2021 FY 2020
IV Quarter December - 0.00 0.00 0.00
III Quarter September - 0.00 0.00 0.00
II Quarter June - 0.00 0.00 0.00
I Quarter March 0.00 0.00 0.00 0.00
FY   0.00 0.00 0.00 0.00



RGRX Capital Expenditures first quarter 2023 Y/Y Growth Comment
Regenerx Biopharmaceuticals inc in the first quarter 2023 recorded Capital Expenditures of $ 0.00 millions.

According to the results reported in the first quarter 2023, Regenerx Biopharmaceuticals Inc achieved the best Capital Expenditures growth in Major Pharmaceutical Preparations industry. While Regenerx Biopharmaceuticals Inc ' s Capital Expenditures no change of % ranks overall at the positon no. in the first quarter 2023.




RGRX Capital Expenditures ( Y/Y Growth %) 2023
2022 2021 2020
IV Quarter December - - - -
III Quarter September - - - -
II Quarter June - - - -
I Quarter March - - - -
FY   - - - -

Financial Statements
Regenerx Biopharmaceuticals Inc 's first quarter 2023 Capital Expenditures $ 0.00 millions RGRX's Income Statement
Regenerx Biopharmaceuticals Inc 's first quarter 2022 Capital Expenditures $ 0.00 millions Quarterly RGRX's Income Statement
New: More RGRX's historic Capital Expenditures Growth >>


RGRX Capital Expenditures (Quarter on Quarter Growth %)

2023
2022 2021 2020
IV Quarter December - - - -
III Quarter September - - - -
II Quarter June - - - -
I Quarter March - - - -
FY (Year on Year)   - - - -




Capital Expenditures first quarter 2023 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall #

Capital Expenditures Y/Y Growth Statistics
High Average Low
0 % 0 % 0 %
 
Capital Expenditures first quarter 2023 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall #
Capital Expenditures Y/Y Growth Statistics
High Average Low
0 % 0 % 0 %
 

Capital Expenditures by Quarter for the Fiscal Years 2020, 2021, 2022, 2023

Regenerx Biopharmaceuticals Inc 's Q/Q Capital Expenditures Growth


Capital Expenditures Q/Q Growth Statistics
High Average Low
0 % 0 % 0 %
 


RGRX's I. Quarter Q/Q Capital Expenditures Comment


Capital Expenditures Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall #
Capital Expenditures Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall #
Capital Expenditures Q/Q Growth Statistics
High Average Low
0 % 0 % 0 %
 


RGRX's I. Quarter Q/Q Capital Expenditures Comment


Regenerx Biopharmaceuticals Inc 's 12 Months Capital Expenditures Growth Year on Year


Capital Expenditures TTM Growth

12 Months Ending
(Mar 31 2023)
12 Months Ending
(Dec 31 2022)
12 Months Ending
(Sep 30 2022)
12 Months Ending
(Jun 30 2022)
12 Months Ending
(Mar 31 2022)
Cumulative Capital Expenditures 12 Months Ending $ 0.00 $ 0.00 $ 0.00 $ 0.00 $ 0.00
Y / Y Capital Expenditures Growth (TTM) - - - - -
Year on Year Capital Expenditures Growth Overall Ranking # # # # #
Seqeuential Capital Expenditures Change (TTM) - - - - -
Seq. Capital Expenditures Growth (TTM) Overall Ranking # # # # #




Cumulative Capital Expenditures growth Comment
In the Mar 31 2023 period, Regenerx Biopharmaceuticals Inc 's cumulative trailing twelve month Capital Expenditures remained unchanged compare to the same period a year ago.

Regenerx Biopharmaceuticals inc achieved highest trailing twelve month year on year Capital Expenditures growth. While overall Capital Expenditures growth ranking, remained unchanged compare to the previous quarter at no. .

Capital Expenditures TTM Q/Q Growth Statistics
High Average Low
0 %
0 %
0 %
 

Capital Expenditures TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall #

Capital Expenditures TTM Y/Y Growth Statistics
High Average Low
0 %
0 %
0 %
 


Capital Expenditures TTM Q/Q Growth Company Ranking
Within: No.
Industry #
Sector #
S&P 500 #
Cumulative Capital Expenditures growth Comment
In the Mar 31 2023 period, Regenerx Biopharmaceuticals Inc 's cumulative trailing twelve month Capital Expenditures remained unchanged compare to the same period a year ago.

Regenerx Biopharmaceuticals inc achieved highest trailing twelve month year on year Capital Expenditures growth. While overall Capital Expenditures growth ranking, remained unchanged compare to the previous quarter at no. .

Capital Expenditures TTM Q/Q Growth Statistics
High Average Low
0 %
0 %
0 %
 


Capital Expenditures TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall #

Capital Expenditures TTM Y/Y Growth Statistics
High Average Low
0 %
0 %
0 %
 


Capital Expenditures TTM Q/Q Growth Company Ranking
Within: No.
Industry #
Sector #
S&P 500 #




Other Capital Expenditures Growth
Major Pharmaceutical Preparations Industry Capital Expenditures Growth Trends and Statistics
Healthcare Sector Capital Expenditures Growth Statistics
Capital Expenditures Growth Trends for overall market
RGRX's Capital Expenditures Growth Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Capital Expenditures Growth
Lowest Ranking Capital Expenditures Growth
Capital Expenditures Growth for RGRX's Competitors
Capital Expenditures Growth for Regenerx Biopharmaceuticals Inc 's Suppliers
Capital Expenditures Growth for RGRX's Customers

You may also want to know
RGRX's Annual Growth Rates RGRX's Profitability Ratios RGRX's Asset Turnover Ratio RGRX's Dividend Growth
RGRX's Roe RGRX's Valuation Ratios RGRX's Financial Strength Ratios RGRX's Dividend Payout Ratio
RGRX's Roa RGRX's Inventory Turnover Ratio RGRX's Growth Rates RGRX's Dividend Comparisons



Companies with similar Capital Expenditures no change for the quarter ending Mar 31 2023 within Healthcare SectorY/Y Change %Capital Expenditures for the quarter ending Mar 31 2023
Treace Medical Concepts Inc -0.20%$ -0.203 millions
Surgalign Holdings Inc -0.75%$ -0.745 millions
Pediatrix Medical Group Inc -2.04%$ -2.043 millions
Rani Therapeutics Holdings Inc -2.36%$ -2.362 millions
Repare Therapeutics Inc -2.46%$ -2.464 millions
Longeveron Inc -2.54%$ -2.542 millions
Sonida Senior Living Inc -2.74%$ -2.741 millions
Organovo Holdings Inc -3.18%$ -3.178 millions
The Pennant Group Inc -3.26%$ -3.261 millions
Psychemedics Corp-4.65%$ -4.651 millions
Adaptive Biotechnologies Corporation-4.97%$ -4.972 millions
Dynavax Technologies Corporation-5.52%$ -5.523 millions
Idexx Laboratories Inc-5.56%$ -5.562 millions
Xtant Medical Holdings Inc -5.79%$ -5.785 millions
Ufp Technologies Inc -6.64%$ -6.641 millions
Revolution Medicines Inc -6.93%$ -6.935 millions
Skye Bioscience Inc -6.95%$ -6.953 millions
Biocept Inc -7.14%$ -7.143 millions
Invacare Holdings Corporation-7.18%$ -7.180 millions
Neoleukin Therapeutics Inc -7.30%$ -7.301 millions
Iqvia Holdings Inc -7.34%$ -7.345 millions
Zimvie Inc -7.82%$ -7.816 millions
Vaxart Inc -7.95%$ -7.949 millions
Urogen Pharma Ltd -8.00%$ -8.000 millions
Boston Scientific Corporation-8.26%$ -8.264 millions
Myomo Inc -9.61%$ -9.611 millions
Jasper Therapeutics Inc -10.34%$ -10.345 millions
Bausch Health Companies Inc -10.53%$ -10.526 millions
Airsculpt Technologies Inc -10.74%$ -10.739 millions
Paratek Pharmaceuticals Inc -11.11%$ -11.111 millions




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com